View More Recent Stories

Apr 1, 2025 08:15AM Clearmind Medicine (CMND) Launches EDC System
Mar 21, 2025 09:28AM Clearmind Medicine's (CMND) Clinical Trial for CMND-100 Moves Forward as Drug Arrives in the U.S.
Mar 19, 2025 07:37AM Clearmind Medicine (CMND) to Evaluate Intranasal Delivery of Its Psychedelic Drug Combination
Mar 18, 2025 07:32AM Clearmind Medicine (CMND) Announces Initiation of First in Human Clinical Trial with CMND-100 in Alcohol Use Disorder Patients
Mar 10, 2025 07:27AM Clearmind Medicine (CMND) Announces Publication of Patent for Cocaine Addiction Psychedelic Combination Treatment in South Korea
Feb 4, 2025 08:35AM Clearmind Medicine (CMND) Announces Publication of Patent for Binge Behavior Psychedelic Combination Treatment in Mexico
Jan 6, 2025 08:15AM Clearmind Medicine (CMND) Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment
Jan 6, 2025 07:50AM SciSparc (SPRC) and Clearmind (CNMD) Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment
Dec 26, 2024 07:02AM Clearmind Medicine (CMND) Looks to Move Forward with its Novel Psychedelic MEAI- Based Alcohol Substitute
Dec 24, 2024 06:55AM Clearmind Medicine (CMND) Receives IRB Approval for its FDA-Regulated Clinical Trial
Dec 16, 2024 08:46AM Clearmind Medicine (CMND) and Dr Glitter Pty Ltd Sign Term Sheet for Mutual Development of Novel Psychedelic MEAI- Based Alcohol Substitute in ActivCrystal Format
Oct 10, 2024 08:07AM Clearmind Medicine (CMND) Announces IRB Approval for FDA First-In-Human Clinical Trial of CMND-100
Sep 16, 2024 04:06PM Clearmind Medicine (CMND) Announces the Notice of an International Patent Application for Pioneering Ibogaine Combination Therapy
Sep 12, 2024 08:20AM Clearmind Medicine (CMND) and Yissum File International Patent Application for Revolutionary Psychedelic Compounds for PTSD Treatment
Sep 6, 2024 07:56AM Clearmind Medicine (CMND) Announces Publication of International Patent Application for Innovative MDMA-Based Combination Treatment
Aug 29, 2024 04:26PM Clearmind Medicine (CMND) Announces Publication of its Patent Application for Innovative Ketamine-Based Combination Treatment
Aug 21, 2024 04:13PM Clearmind Medicine (CMND) Granted U.S. Patent Approval for Binge Behavior Treatment
Aug 16, 2024 04:14PM Clearmind Medicine (CMND) and Yissum Expand Collaboration with International Patent Application for Generation 3.0 Psychedelic Compounds to Treat Mental Disorders
Aug 6, 2024 08:58AM SciSparc (SPRC) and Clearmind Medicine (CNMD) Announce New Scientific Article Showing MEAI Potential as a Novel Weight Loss Drug
Jul 19, 2024 07:55AM Clearmind Medicine (CMND) Signs Agreement to Source Manufacturers and Distributors for its Alcohol Substitute Beverage Product
Jul 16, 2024 09:02AM Clearmind Medicine (CMND) Obtains IND Approval from the FDA to Start the Phase I/IIa Clinical Trial with its Treatment for Alcoholism
Jul 16, 2024 06:03AM SciSparc (SPRC) Announces U.S. Patent Application for Treating Metabolic Syndrome and Weight Loss
Jun 28, 2024 07:55AM Clearmind Medicine (CMND) Granted Patent Approval in HK for its Binge Behaviors Treatment
Jun 20, 2024 07:57AM Clearmind Medicine (CMND) Secures Exclusive Global Rights to Innovative Psychedelic Compounds for PTSD Treatment
Jun 11, 2024 07:45AM Clearmind Medicine (CMND) announces advancement in its proprietary MEAI- based alcohol substitute beverage program
View More Recent Stories